Aditya Bardia, MD, MPH, FASCO

Aditya Bardia, MD, MPH, FASCO, is a professor in the Department of Medicine, Division of Hematology/Oncology and director of Translational Research Integration at UCLA Health Jonsson Comprehensive Cancer Center.

Articles by Aditya Bardia, MD, MPH, FASCO

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 1st 2022

Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

August 1st 2022

A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

ByAditya Bardia, MD, MPH, FASCO

July 29th 2022

Aditya Bardia, MD, MPH, discusses the need for oral selective estrogen receptor degraders in ESR1-mutant, estrogen receptor–positive breast cancer.

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 25th 2022

Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 25th 2022

Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 18th 2022

Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.

Frontline Combination Strategies in HR+/HER2- BC

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 18th 2022

A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 11th 2022

Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Komal Jhaveri, MD, FACP,Mark D. Pegram, MD,Anne P. O’Dea, MD

July 11th 2022

Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

ByAditya Bardia, MD, MPH, FASCO

March 14th 2022

Aditya Bardia, MD, MPH, discusses the use of endocrine therapy in estrogen receptor–positive breast cancer.

Practical Advice on the Use of ctDNA Testing in Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Barry P. Rosen, MD

February 16th 2022

Closing out their discussion on circulating tumor DNA in breast cancer management, experts share closing advice on practical strategies to use testing in clinic.

Other Clinical Studies on ctDNA Use in Breast Cancer

ByBarry P. Rosen, MD ,Aditya Bardia, MD, MPH, FASCO

February 16th 2022

Shared insight on how clinical trial data behind circulating tumor DNA in breast cancer may affect future treatment strategies.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

BySara A. Hurvitz, MD,Aditya Bardia, MD, MPH, FASCO,Patrick Neven, MD, PhD,Kevin Kalinsky, MD, MS

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection

ByAditya Bardia, MD, MPH, FASCO,Barry P. Rosen, MD

February 9th 2022

A brief synopsis on the use of circulating tumor DNA for cancer detection versus treatment selection in breast cancer management.

Role of ctDNA in the Adjuvant Setting of Breast Cancer

ByAditya Bardia, MD, MPH, FASCO,Barry P. Rosen, MD

February 9th 2022

Aditya Bardia, MD, MPH, and Barry Rosen, MD, discuss the role of circulating tumor DNA in the adjuvant setting of breast cancer.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

BySara A. Hurvitz, MD,Aditya Bardia, MD, MPH, FASCO,Patrick Neven, MD, PhD,Kevin Kalinsky, MD, MS

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

SABCS 2021 Updates in ER+ Breast Cancer

BySara A. Hurvitz, MD,Aditya Bardia, MD, MPH, FASCO,Patrick Neven, MD, PhD,Kevin Kalinsky, MD, MS

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Aditya Bardia, MD, MPH, FASCO

Articles by Aditya Bardia, MD, MPH, FASCO

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors

Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs

Dr. Bardia on the Need for Oral SERDs in ESR1-Mutant ER+ Breast Cancer

HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?

Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer

Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?

Frontline Combination Strategies in HR+/HER2- BC

Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition

Dr. Bardia on the Rationale of Utilizing Endocrine Therapy in ER+ Breast Cancer

Practical Advice on the Use of ctDNA Testing in Breast Cancer

Other Clinical Studies on ctDNA Use in Breast Cancer

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

ctDNA in Breast Cancer: Cancer Detection Vs Therapy Selection

Role of ctDNA in the Adjuvant Setting of Breast Cancer

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

SABCS 2021 Updates in ER+ Breast Cancer

Trending on OncLive

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer

Dana-Farber Study Finds Dual Immunotherapy May Help Certain Patients With Advanced NSCLC Live Longer